FDA Reviews Peptides for the 503A Compounding List: PCAC Meeting on July 23-24, 2026 (BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon)
FDA committee PCAC meets July 23-24, 2026 on seven peptides for the 503A compounding list. What it is and why it does not change EU research status.
TL;DR: What this is about
Date: July 23-24, 2026, FDA White Oak Campus, Silver Spring, Maryland (with a virtual attendance option). Announced in the US Federal Register on April 16, 2026. What is happening: The Pharmacy Compounding Advisory Committee (PCAC) of the US FDA discusses and votes on whether seven peptides should be placed on the so-called 503A bulk substances list, which would make these substances available for pharmacy compounding in the United States. Which peptides: Day 1 (July 23): BPC-157, KPV, TB-500, MOTS-c. Day 2 (July 24): Emideltide (DSIP), Semax, Epitalon. Each as free base and as acetate. Important context: This is a US advisory step, not an approval. The committee only issues a recommendation, and the FDA decides afterward. For the EU: The process does not change the research status of these compounds in the EU. They remain "research use only".
Note: This article serves exclusively scientific information and research purposes. The peptides mentioned are research compounds and not intended for human consumption. We describe a US regulatory process as well as published study data, not human applications.
What the FDA Discusses on July 23 and 24, 2026
On April 16, 2026, the FDA announced a meeting of its Pharmacy Compounding Advisory Committee (PCAC) in the US Federal Register (FR document 2026-07361). The committee meets on July 23 and 24, 2026 at the FDA White Oak Campus in Silver Spring, Maryland. Virtual attendance is possible, and the meeting will be streamed online, captioned, and recorded.
The substance of the matter is a specific regulatory question: Should seven nominated peptides be placed on the list of bulk substances under Section 503A of the US Federal Food, Drug, and Cosmetic Act? This list governs which active substances US pharmacies may use in the context of so-called compounding (the individual preparation of formulations) when neither a USP/NF monograph nor an approved drug exists as a source for the substance.
The seven peptides were previously in a category that the FDA classifies as substances with relevant open safety and data questions (often referred to as "Category 2"). This is precisely why a formal hearing is now taking place: The committee is to review the available evidence and give the FDA a recommendation.
The associated public docket carries the number FDA-2025-N-6895. Comments received by July 9, 2026 will be presented to the committee before the meeting. The docket closes on July 22, 2026, and the FDA still incorporates later comments into its own evaluation.
The Seven Peptides and Their Nominated Indications
The Federal Register notice lists each peptide together with the indications for which it was nominated for compounding. Important: These are the application areas named in the nomination, not proven or approved effects. They merely show what an inclusion was requested for.
Day 1, July 23, 2026:
- BPC-157 (free base and acetate): nominated with reference to ulcerative colitis.
- KPV (free base and acetate): nominated with reference to wound healing and inflammatory conditions.
- TB-500 (free base and acetate): nominated with reference to wound healing.
- MOTS-c (free base and acetate): nominated with reference to obesity and osteoporosis.
Day 2, July 24, 2026:
- Emideltide (DSIP) (free base and acetate): nominated with reference to opioid withdrawal, insomnia, and narcolepsy. We do not carry this peptide.
- Semax (free base and acetate): nominated with reference to cerebral ischemia, migraine, and trigeminal neuralgia.
- Epitalon (free base and acetate): nominated with reference to insomnia.
Six of the seven compounds are research compounds that we carry as laboratory reagents in our catalog. Grouped here, with links to the respective product page:
Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.
Active fragment of Thymosin Beta-4, a naturally occurring repair protein. Promotes cell migration and new blood vessel formation for systemic tissue healing. Especially researched for muscle, tendon, and cardiac repair.
Anti-inflammatory tripeptide derived from alpha-MSH (positions 11-13). Inhibits NF-kB signaling, supports gut barrier integrity, and shows antimicrobial activity. A targeted approach to inflammation research without broad immunosuppression.
Mitochondrial-derived signaling peptide (16 amino acids) that mimics the effects of exercise at the cellular level. Activates AMPK, improves glucose uptake, and enhances fat metabolism - a key tool in metabolic and longevity research.
Brain-boosting nootropic peptide derived from ACTH. Increases BDNF (brain-derived neurotrophic factor), enhances focus, memory, and mental clarity. Widely used in Russian clinical practice for cognitive enhancement.
Tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. One of the most studied peptides in longevity research, developed by Prof. Khavinson at the St. Petersburg Institute of Bioregulation.
"Advisory" Is Not "Approval": The Process in Detail
This is the central point that gets lost in many headlines. The PCAC is an advisory committee. It issues recommendations to the FDA and makes no binding decisions. An analysis by the law firm Foley & Lardner LLP dated May 5, 2026 describes the process soberly: The committee reviews the available evidence and votes on whether it recommends an inclusion. Only afterward does the FDA decide for itself. If it concludes that a substance is suitable, it must initiate a formal rulemaking process to actually place it on the 503A list.
In other words: Even a positive recommendation from the committee on July 23 or 24 would only be an intermediate step. The agency decision follows, then possibly a rulemaking process. And even an entry on the 503A list is not a drug approval: It merely makes a substance available for pharmacy compounding in the United States, under the requirements applicable there.
Investigational, not approved
None of the seven peptides is approved by the FDA as a drug. The FDA notice explicitly points out that open safety and data questions exist for these substances. The PCAC step is a hearing on exactly these questions, not proof of efficacy. All compounds remain investigational (under study), not approved.
Why BPC-157 Is a Good Case Study: The State of the Data
How thin the clinical data basis actually is becomes clear from a recent review on BPC-157 in the journal Pharmaceutics (May 20, 2026, 18(5):625, PMID 42198317). It is interesting because it does not call the biology into question but rather the pharmaceutical maturity.
What the BPC-157 review (Pharmaceutics 2026) reports
Type: Review that summarizes preclinical and human data on BPC-157. Human data: A total of fewer than 30 subjects, spread across three uncontrolled pilot studies. None of them used a standardized pharmaceutical preparation, and none was a randomized controlled trial. Pharmacokinetics: Reported plasma half-life under 30 minutes (preclinically and in a preliminary pilot trial with two subjects), while the reported biological effects are said to persist over hours to days. This discrepancy between short half-life and long described activity has not been resolved to date. Animal model: A cited formal preclinical ADME study in two species reports linear, dose-proportional kinetics and an intramuscular bioavailability of 14 to 51 percent, depending on the species. Formulation: No characterized, validated formulation of pharmaceutical quality exists. Among other things, BCS classification, permeability data, and formal compatibility studies of the excipients are lacking. Authors' conclusion: The main hurdle for clinical translation is not the absence of biological activity but the absence of fundamental pharmaceutical science: characterized formulations, validated pharmacokinetics, and a coherent development strategy.
This is an important finding for putting the entire PCAC discussion into context. According to this paper, the bottleneck lies less in the question "does the molecule basically work in the model" than in the question "is there a defined, reproducible, quality-assured preparation with robust pharmacokinetics in humans". For inclusion on a compounding list, exactly that is relevant, because compounding presupposes a manageable, characterized bulk active substance.
There is also a structural problem that several sources mention: A large part of BPC-157 research originates from a single research group, which limits independent replication. And because the peptide is derived from a naturally occurring protein, patent hurdles exist that dampen the commercial incentive for expensive Phase 3 programs.
What This Means for Research in the EU
The entire process is a US regulatory process. The 503A bulk substances list is an instrument of US law and concerns compounding in US pharmacies. It has no immediate effect on the legal status of these compounds in the European Union.
In the EU, the peptides mentioned remain what they are: research compounds for laboratory use, "research use only", not intended for human consumption, and not approved as drugs. An inclusion on the US 503A list, even if it were to occur after the meeting and the downstream FDA procedure, would not change that.
For the research community, the genuinely interesting part is therefore not the headline but the material submitted to the public docket FDA-2025-N-6895 ahead of the meeting: the compiled preclinical and clinical evidence, the safety assessments, and the scientific discussion on each of the seven peptides. This is a rare, bundled inventory of the state of the data.
No change to application or status
This article describes an advisory and hearing step by a US agency. It is not a recommendation, not a statement about efficacy or safety, and not a statement about any application in humans. The research status of the compounds mentioned in the EU remains unchanged.
FAQ
Sources
- Federal Register: "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List." Published April 16, 2026, FR document 2026-07361, Docket FDA-2025-N-6895. https://www.govinfo.gov/content/pkg/FR-2026-04-16/html/2026-07361.htm
- Foley & Lardner LLP: "FDA to Consider Lifting Restrictions on Numerous Compounded Peptides." May 5, 2026. https://www.foley.com/insights/publications/2026/05/fda-to-consider-lifting-restrictions-on-numerous-compounded-peptides/
- BPC-157 review. Pharmaceutics. 2026;18(5):625. PMID 42198317. https://pubmed.ncbi.nlm.nih.gov/42198317/
Research disclaimer: All content serves exclusively scientific information and research. The peptides mentioned are research compounds and not intended for human consumption (research use only). No statements are made about efficacy, safety, or any application in humans.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.